All in all, the documented immunoexpression patterns for WT1 and TDs in RCC tumor cells, TMS, and tumor-adjacent HRT generate numerous hypotheses about the origins and biology of RCCs and, potentially, may even inform kidney cancer therapeutics. This evidence concerns the gene WT1 and renal cell carcinoma.